Impact of national guidelines on use of BRCA1/2 germline testing, risk management advice given to women with pathogenic BRCA1/2 variants and uptake of advice

Table 4 Number and percentages of carriers concordant with risk management strategies based on interviews (n = 313)

Risk management strategy	Carriers concordant n = 313 n (%)
RRBM ≤40 years^a	70/169 (41)
RRSO ≤40 years^a	127/169 (75)
30–50 years - annual MRI + MMG (if MRI unavailable, annual MMG + US), consider 6-month interval US +CBE^b	92/95 (97)
> 50 years - annual MMG+/− US+ CBE^c	46/50 (92)
If pregnant - no MRI or MMG, consider US^d	14 /18 (78)
Risk-reducing medication in women (such as tamoxifen or raloxifene)^e	6/100 (6)
Has the patient been told that serum CA125 and/or transvaginal ultrasound (TVU) is not recommended?	176/301 (58)

Legend: RRBM Risk-reducing bilateral mastectomy, RRSO Risk-reducing salpingo-oophorectomy, MRI Magnetic resonance screening, MMG Mammography, US Ultrasound, CBE Clinical breast examination, HRT Hormone replacement therapy. ^aIncludes only women aged > 40 years as the denominator. ^bIncludes only women aged 30 to 50 who have not had RRBM. ^cIncludes only women > 50 years who have not had RRBM. ^dIncludes only pregnant women who have not had RRBM. ^eIncludes only women who have not had RRBM

ISSN: 1897-4287